The difference between information and
expert, data-driven actionable intelligence
Welcome to the May 2015 issue of CMC Market Outlook
This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.
Enjoy the May issue!
Serialization Requirements May Drive Pharmaceutical Companies to Re-examine Their CMO Use
Bio/pharmaceutical serialization will soon be a reality around the world, and the effort to comply with the complexity involved with compliance is likely to create winners and losers in the Contract Manufacturing Organization (CMO) industry.
Serialization, sometimes known as track-and-trace, refers to systems-usually country-specific-used to track the passage of bio/pharmaceutical products through the supply chain to dispensing at the hospital or pharmacy level. Generally speaking, regulations require that… read on
How big is the market for…?
This is a handy guide to frequently requested data about the bio/pharma contract services industry.
The market for innovator API development and manufacturing – outsourced spending:
|2014: $13-15 billion||Cambrex
Presentation at Oppenheimer Conference
Read more about the size of the contract services market for various segments.
WuXi Focuses On Expansion with $165 Million Loan, Subsidiary Stock Offering and New Offices
WuXi PharmaTech appears to be gearing up to expand its manufacturing capacity and boost its services from discovery all the way through commercial manufacturing.
WuXi is borrowing up to $165 million from a consortium of banks in Asia, led by Citibank, to help fund new manufacturing capacity. The loan will help fund a nearly $150 million effort to double small molecule API manufacturing capacity at WuXi’s Changzhou facilities by late 2015 or early 2016. WuXi is also building… read on
Big Pharma Feeds Big CMO Growth
by Jim Miller, President, PharmSource
Size has proven to be a major competitive advantage in the clinical contract research organization (CRO) industry, and if that experience is any guide, it presages how the dose CMO industry will evolve as well.
The seven largest clinical CROs, six of which are public companies today, accounted for 52% of bio/pharmaceutical industry spending on CRO services in 2014, up from… read on
PharmSource STRATEGIC ADVANTAGE
PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.
See for yourself how this resource gives you vital tools for understanding the industry.
To request a test-drive today, contact Nathaniel Celentano at firstname.lastname@example.org / +1-703-383-4903, ext. 112 (ET USA).